Trial Profile
A Single-center, Open-label, Single-dose, Phase 1 Study to Evaluate the Pharmacokinetics of ACT-541468 in Subjects With Mild, Moderate, and Severe Hepatic Impairment
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 19 Aug 2021
Price :
$35
*
At a glance
- Drugs Daridorexant (Primary)
- Indications Insomnia; Sleep apnoea syndrome
- Focus Adverse reactions
- Sponsors Idorsia Pharmaceuticals
- 29 Jun 2021 Results (n=24) presented at the European Association for Clinical Pharmacology and Therapeutics Virtual Meeting 2021
- 18 May 2021 Results (n=24) assessing safety and pharmacokinetics of daridorexant in subjects with mild and moderate hepatic impairment in comparison with healthy subjects, published in the Clinical Pharmacokinetics.
- 01 Jul 2020 Status changed from recruiting to completed.